Based on the Panbela Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Panbela Therapeutics Inc is not available over the next 12 months. Panbela Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Panbela Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Panbela Therapeutics Inc’s stock price was USD 0.34. Panbela Therapeutics Inc’s stock price has changed by +1.98% over the past week, -1.37% over the past month and -98.07% over the last year.
No recent analyst target price found for Panbela Therapeutics Inc
No recent average analyst rating found for Panbela Therapeutics Inc
Company Overview Panbela Therapeutics Inc
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. Read Less
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine anal...Read More
Frequently Asked Questions About Panbela Therapeutics Inc (PBLA) Stock
Stock Target Advisor's fundamental analysis for Panbela Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on PBLA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PBLA's stock to indicate what its average analyst target is.
PBLA stock's Price/Earning ratio is 0.00.
Our analysis grades PBLA stock's Price / Earning ratio at A-. This means that PBLA stock's Price/Earning ratio is above 7.999999999999996% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PBLA may be undervalued for its sector.
The last closing price of PBLA's stock was USD 0.34.
The most recent market capitalization for PBLA is USD 1.56M.
Unfortunately we do not have enough analyst data on PBLA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Panbela Therapeutics Inc's stock.
As per our most recent records Panbela Therapeutics Inc has 7 Employees.
Panbela Therapeutics Inc's registered address is 712 Vista Boulevard, Waconia, MN, United States, 55387.
You can get more information about it from Panbela Therapeutics Inc's website at https://www.panbela.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Panbela Therapeutics Inc (PBLA) Stock
Stock Target Advisor's fundamental analysis for Panbela Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on PBLA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PBLA's stock to indicate what its average analyst target is.
PBLA stock's Price/Earning ratio is 0.00.
Our analysis grades PBLA stock's Price / Earning ratio at A-. This means that PBLA stock's Price/Earning ratio is above 7.999999999999996% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PBLA may be undervalued for its sector.
The last closing price of PBLA's stock was USD 0.34.
The most recent market capitalization for PBLA is USD 1.56M.
Unfortunately we do not have enough analyst data on PBLA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Panbela Therapeutics Inc's stock.
As per our most recent records Panbela Therapeutics Inc has 7 Employees.
Panbela Therapeutics Inc's registered address is 712 Vista Boulevard, Waconia, MN, United States, 55387.
You can get more information about it from Panbela Therapeutics Inc's website at https://www.panbela.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PBLA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
